Everads Announces Publication of First-in-Human Clinical Data for Its Suprachoroidal Injector in Ophthalmology Science and Three Presentations at ARVO 2026

– Publication reports favorable safety, tolerability, and device performance, while highlighting posteriorly directed drug distribution as visualized by thermal imaging – TEL AVIV, Israel, May 3, 2026 /PRNewswire/ -- Everads Therapy, a clinical-stage company leveraging its novel...